Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 113 publications

Most recent new publication 4/2025

See all their publications

Vacancies in this group

Working in this group

Postdoctoral Training Fellow

  • Chelsea
  • Structural Biology
  • Salary Range: £45,600 - £55,000 per annum
  • Fixed term

Under the leadership of Claudio Alfieri, we are seeking to appoint a Postdoctoral Training Fellow to join the Molecular Mechanisms of Cell Cycle Regulation Group at the Chester Beatty Laboratories, Fulham Road in London. This project aims to investigate the molecular mechanisms of cell cycle regulation by macromolecular complexes involved in cell proliferation decisions, by combining genome engineering, proteomics and in situ structural biology. For general information on Post Doc's at The ICR can be found here. Key Requirements The successful candidate must have a PhD in cellular biochemistry and experience in Cryo-EM and CLEM is desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 7 years Department/Directorate Information: The candidate will work in the Molecular Mechanisms of Cell Cycle Regulation Group within the ICR Division of Structural Biology headed by Prof. Laurence Pearl and Prof. Sebastian Guettler. The division has state-of-the-art facilities for protein expression and biophysics/x-ray crystallography, in particular the Electron Microscopy Facility is equipped with a Glacios 200kV with Falcon 4i detector with Selectris energy filter and the ICR has access to Krios microscopes via eBIC and the LonCEM consortium. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Claudio Alfieri via Email on [email protected]

Higher Scientific Officer - Drug Discovery Biology, Centre for Protein Degradation

  • Sutton
  • Cancer Therapeutics
  • £39,805 - £49,023
  • Fixed term

We are seeking to recruit a Higher Scientific Officer within the Induced Proximity Therapeutics (IPT) Team in the ICR Centre for Protein Degradation to support our molecular glue and PROTAC drug discovery projects and expand induced proximity technology. The IPT team focuses on three main areas of research: Cancer target validation Screening, profiling and molecular mechanism of action of molecular glue and PROTAC degraders Novel E3 ligase biology and ligand discovery The successful candidate will work in a multidisciplinary team and play a key role in target validation, developing in vitro and cell-based assays, and pharmacological characterisation of novel molecular glue degraders and PROTACs, but may also contribute to other activities. About you The successful candidate: Will be a strong team player who is technically minded and passionate about science and cancer drug discovery Will hold a first degree, and preferably a PhD, in biological science or biochemistry Will have experience in cancer biology/target validation, genetic manipulation techniques, in vitro and cell-based assay development and pharmacological compound profiling Experience in targeted protein degradation will be a significant advantage. Department/Directorate Information This position will be based in the ICR's Centre for Protein Degradation, a part of the Centre for Cancer Drug Discovery (CCDD) specialising in developing novel drug modalities that re-wire tumour cells' signalling by targeted degradation of key oncogenic drivers. Our experienced biologists work closely with medicinal chemists, biophysicists, computational scientists, oncology specialists and physicians on discovering new medicines - molecular glue degraders and PROTACs - using innovative screening platforms and characterising their mechanisms of action, as well as expanding the repertoire of novel degradable drug targets and E3 ligases (enzymes that mediate protein degradation). Our research provides a nucleus for the academics and pharmaceutical industry to explore therapeutic potential of targeted protein degradation from laboratory hypothesis-testing to early clinical trials, for the benefit of cancer patients. What we offer A dynamic and supportive research environment in one of the successful academic cancer drug discovery centres in the UK Access to state-of-the-art facilities and professional development Collaboration with leading drug discovery and oncology scientist Competitive salary and pension To learn more about this role, please download the attached job pack. For informal inquiries, please contact Dr Agnieszka Konopacka, Group Leader, Induced Proximity Therapeutics, Centre for Protein Degradation via email: [email protected].

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

14/04/25

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned.

According to a new modelling study, published in the journal JAMA Internal Medicine, the high number of CT (computed tomography) scans carried out in the United States in 2023 could cause 5 per cent of all cancers in the country, equal to the number of cancers caused by alcohol.

CT scans increase the risk of cancer due to the use of ionising radiation. The risk to individuals is low and benefits most often outweigh the risks, as long as the scan is clinically justified.

93 million CT scans carried out in 2023

However, a team of researchers from The Institute of Cancer Research, London, Kaiser Permanente Washington, Seattle, and the University of California, San Francisco, are concerned about the increasing radiation doses used in CT scans and the rising rates of use in the US. Since 2009, the number of CT scans carried out in the US has risen by 30 per cent.

The research team calculated the number of cancers expected in future in the US population that will be linked to the 93 million CT scans carried out on 62 million people in 2023.

Using a publicly available risk model developed by Professor Amy Berrington, Leader of the Clinical Cancer Epidemiology Group at The Institute of Cancer Research (ICR) on lifetime cancer risk after exposure to radiation, combined with US data on the number of CT scans and doses, the team estimated the numbers and types of cancers that were expected in both children and adults.

9,700 cancers in children

Their model found that the CT scans carried out in 2.5 million children would result in 9,700 cancers. Although cancer risk from radiation is higher in children, CT scans were carried out more frequently in adults, resulting in more expected cancers in the older population.

Organ sensitivity to radiation varies at different ages. In adults, future cancers are likely to be linked to chest and abdomen CTs, whereas in children, brain CT scans carry a higher risk.

CT scans are an important imaging technique used to diagnose cancers, detect bone injuries, and to guide treatments. The researchers emphasise that benefits to the individual will outweigh the risks if the scan is clinically justified – it will impact clinical decision making – and the dose is adjusted to the person’s age and the organ being targeted. However, as the number of CT scans rises across the population, more radiation-linked cancers are expected.

CT scans must be clinically justified

In the UK, regulations mean that CT scan requests are reviewed by radiologists and only carried out when clinically justified and with optimised doses. Because of this, the UK has one of the lowest rates of CT scans per population in OECD countries – less than 100 scans per 1,000 people, compared with over 250 scans per 1,000 people in the US. Research studies have provided evidence that CT scans used in targeted screening on healthy people, such as for lung cancer, will save lives, and that the benefits outweigh the risks.

However, the researchers argue that the risk of cancer outweighs any potential benefit from the whole-body scans offered by private clinics to healthy people.

'Small risks do add up'

Professor Amy Berrington, Leader of the Clinical Cancer Epidemiology Group at The Institute of Cancer Research, London, who co-led the study, said:

“While CT scans are immensely beneficial in diagnosing and detecting many conditions, including cancer, they do involve exposure to ionising radiation that has been shown to increase the risk of developing cancer. It’s important to note that for the individual patient, this increased risk is small, and the benefits far outweigh the risks if the scan is clinically justified. But when millions of CT scans are being carried out across the population, these small risks do add up. In the US, CT-related cancers could now account for 5 per cent of all cancers – some of these cancers could be prevented by avoiding unnecessary scans and ensuring correct doses are used.

“While the NHS in the UK has a much better system to ensure that CT scans are clinically justified, we must not get complacent. Many other countries in Europe and also Australia perform high numbers of scans – and these numbers are rising. We are urging doctors to ensure that scans are only carried out where necessary, and that doses are appropriate for the patient.”

Dr Rebecca Smith-Bindman, Radiologist and Professor of Epidemiology and Biostatistics, Obstetrics, Gynecology and Reproductive Medicine at the University of California San Francisco, said:

“These future cancer risks can be reduced either by reducing the number of CT scans (particularly low value scans which are used in situations where they are unlikely to help the patient) or by reducing the doses per exam. The doses for CT remain highly variable across patients’ hospitals, even in the UK, and there are opportunities to reduce those doses without reducing the accuracy of the tests.”

Professor Kristian Helin, Chief Executive of The Institute of Cancer Research, London, said:

“CT scans have transformed patient care, and it’s important that people do continue having their scans when they are invited by their doctor.

“This research models the potential impact that CT scans could have on cancer cases, across the whole population. While we search for smarter, kinder treatments for cancer patients, we must also seek to understand how to prevent the disease. This research will add to the growing body of evidence that indicates that CT scans must only be used when necessary for clinical decision making.”